Flutriciclamide (18F-GE180) PET: First-in-human PET study of novel third-generation in vivo marker of human translocator protein
- Fan Z.
- Calsolaro V.
- Atkinson R. A.
- Femminella G. D.
- Waldman A.
- Buckley C.
- Trigg W.
- Brooks D. J.
- Hinz R.
- Edison P.
Publication date
January 2016
DOIAbstract
Neuroinflammation is associated with neurodegenerative disease. PET radioligands targeting the 18-kDa translocator protein (TSPO) have been used as in vivo markers of neuroinflammation, but there is an urgent need for novel probes with improved signal-to-noise ratio. Flutriciclamide (18F-GE180) is a recently developed third-generation TSPO ligand. In this first study, we evaluated the optimum scan duration and kinetic modeling strategies for 18F-GE180 PET in (older) healthy controls
Add to ORKG